No Picture
News

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027 following 23 years of leadership with the… … […]

News

Get to know Drive’s GUSKA

We recently sat down with the five techbio companies accepted into theĀ Fall 2026 Drive cohortĀ to learn more about their science, their ā€œah-haā€ moments, and how Drive is changing the trajectory of their business. Today it’s GUSKA, an AI-powered biotech developing programmable RNA-based oncolytic virotherapies for aggressive solid tumors. We spoke… … […]

No Picture
News

Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die

In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety events. One patient succumbed to leukoencephalopathy while the second experienced sudden death. The post Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After… … […]